The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy

Although several programmed cell death (PD)-1 inhibitors are approved for the first-line treatment of advanced urothelial carcinoma, their efficacy remains unknown in cisplatin-ineligible patients with upper tract urothelial carcinoma (UTUC) compared with gemcitabine plus carboplatin. Data for patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jiwei, Su, Ruopeng, Chen, Zeyu, Jiang, Shuai, Chen, Minfeng, Yuan, Yichu, Hu, Hailong, Fu, Changde, Huang, Zhiyang, Wang, Zhenyu, Zheng, Bing, Li, Chancan, Wang, Zaoyu, Bao, Yige, Cai, Ming, Guo, Jianming, Wei, Qiang, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487735/
https://www.ncbi.nlm.nih.gov/pubmed/36148322
http://dx.doi.org/10.1080/2162402X.2022.2124691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487735/
https://www.ncbi.nlm.nih.gov/pubmed/36148322
http://dx.doi.org/10.1080/2162402X.2022.2124691

Ejemplares similares